Holen Sie sich die Stockscreener-App
2.29
0.00%
0.00
Handel nachbörslich:
2.29
Schlusskurs vom Vortag:
$2.29
Offen:
$2.29
24-Stunden-Volumen:
40,733
Relative Volume:
1.07
Marktkapitalisierung:
$3.22M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.28M
KGV:
-0.7608
EPS:
-3.01
Netto-Cashflow:
$-9.78M
1W Leistung:
-29.54%
1M Leistung:
-57.67%
6M Leistung:
-31.69%
1J Leistung:
-81.89%
1-Tages-Spanne:
$2.17
$2.33
1-Wochen-Bereich:
$2.17
$3.135
52-Wochen-Spanne:
$2.118
$14.67
Ensysce Biosciences Inc Stock (ENSC) Company Profile
Firmenname
Ensysce Biosciences Inc
Sektor
Branche
Telefon
(858) 263-4196
Adresse
7946 IVANHOE AVENUE, LA JOLLA
Vergleichen Sie ENSC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
2.29 | 3.22M | 0 | -11.28M | -9.78M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Ensysce Biosciences Inc Aktie (ENSC) Neueste Nachrichten
After-Hour Gains For Ensysce Biosciences (ENSC) Signal Renewed Interest - Stocks Telegraph
Ensysce Biosciences corrects SEC filing omission By Investing.com - Investing.com South Africa
Ensysce Biosciences corrects SEC filing omission - Investing.com India
Ensysce Biosciences raises $1.1 million in stock sale By Investing.com - Investing.com South Africa
Ensysce Biosciences raises $1.1 million in stock sale - Investing.com
Ensysce Raises Fresh Capital: Strategic $1.1M Investment Powers Next-Gen Pain Drug Pipeline - Stock Titan
Ensysce Biosciences Reminds Shareholders to Vote At Upcoming 2022 Virtual Annual Shareholder Meeting - ACCESS Newswire
(ENSC) On The My Stocks Page - news.stocktradersdaily.com
Ensysce Biosciences Advances in Opioid Innovation - TipRanks
Ensysce Biosciences Stock Price, Quotes and Forecasts | NASDAQ:ENSC - Benzinga
Revolutionary Opioid Safety Technology Takes Center Stage at PAINWeek 2025 - StockTitan
How the (ENSC) price action is used to our Advantage - news.stocktradersdaily.com
Zacks Small Cap Issues Negative Forecast for ENSC Earnings - Defense World
Ensysce Biosciences (ENSC) Projected to Post Earnings on Friday - Defense World
Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC) - EIN News
When Will Ensysce Biosciences, Inc. (NASDAQ:ENSC) Breakeven? - Simply Wall St
Ensysce Biosciences Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Ensysce Biosciences, Inc. SEC 10-K Report - TradingView
Ensysce Biosciences Narrows Losses to $8M, Secures FDA Breakthrough Status - StockTitan
(ENSC) Long Term Investment Analysis - Stock Traders Daily
Ensysce Biosciences to Present Pain Management Innovations at ROTH Conference - StockTitan
Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids - Marketscreener.com
Ensysce Biosciences Releases Updated Investor Presentation Available Via Investor Relations Website - ACCESS Newswire
Ensysce Biosciences Provides Business Update and Reports First Quarter 2022 Financial Results - ACCESS Newswire
Ensysce Biosciences Regains Compliance with Nasdaq - ACCESS Newswire
Ensysce Biosciences Announces Pricing of $4.1 Million Public Offering - ACCESS Newswire
How To Trade (ENSC) - Stock Traders Daily
Revolutionary Pain Management: This New Opioid Actually Prevents Overdose - StockTitan
When Can We Expect A Profit From Ensysce Biosciences, Inc. (NASDAQ:ENSC)? - Yahoo Finance
Ensysce Biosciences Announces Fourth Quarter and Full Year 2021 Earnings Release Date and Timing of Corporate Update Call - ACCESS Newswire
Ensysce Biosciences Announces Key Efficacy Data for Lead Analgesic - ACCESS Newswire
Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium - ACCESS Newswire
Ensysce Biosciences Receives Positive Nasdaq Listing Determination - ACCESS Newswire
Ensysce Biosciences Releases Updated Investor Presentation Ahead of Corporate Update Call - ACCESS Newswire
Ensysce Biosciences Chief Medical Officer to Chair the 17th Annual Pain Therapeutics Summit - ACCESS Newswire
Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate - ACCESS Newswire
Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection - ACCESS Newswire
Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR - NEWSnet
Ensysce reports overdose protection in drug trial - Investing.com
Ensysce's PF614-MPAR Shows Breakthrough Overdose Protection in Phase 1b Opioid Trial - StockTitan
Biotech Steals The Show Following $14 Million Grant Announcement - MSN
Ensysce's Breakthrough Pain Drug Gets FDA Special Status; Secures $23.7M Funding Boost - StockTitan
Ensysce Biosciences (NASDAQ:ENSC) Shares Down 5.6% – Should You Sell? - Defense World
Ensysce Biosciences Regains Full Compliance with Nasdaq - Financial Content
Finanzdaten der Ensysce Biosciences Inc-Aktie (ENSC)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):